Luangxay Thitsamay, Virachith Siriphone, Hando Kiyomi, Vilayvong Soulideth, Xaysomphet Phaengvilay, Arounlangsy Phetsamone, Phongsavan Keokedthong, Mieno Makiko Naka, Honma Naoko, Kitagawa Masanobu, Sawabe Motoji
Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Cancer Center, Mittaphab Hospital, Vientiane, Laos. Email:
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):589-594. doi: 10.31557/APJCP.2019.20.2.589.
Aim: The purpose of this study is to evaluate the prevalence of the immunohistochemical subtypes of breast cancer among Lao women by using immunohistochemistry (according to the St. Gallen 2017 guidelines) and to study their correlation to clinicopathological features in order to help guide better treatment plans for patients. Materials and methods: Formalin-fixed and paraffin embedded tissue blocks of 76 cases of primary invasive breast cancer were retrieved from the University of Health Sciences, Vientiane, Lao PDR, from 2013 to 2016. Patients’ information and previous histological reports were reviewed. Immunohistochemistry was done using antibodies against estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu) and Ki-67 (MIB-1). Results: The mean age of the patients was 49 years, and the major histologic type was invasive ductal carcinoma, NOS (90.7%). The proportion of each subtype was hormone receptor-positive and HER2-negative, 44.7%; hormone receptor-positive and HER2-positive, 3.9%; hormone receptor-negative and HER2-positive, 13.2%; and triple-negative, 38.2%. ER was positive in 40.8% of the cases, while PR was positive in 47.4%. More than half of the cases were poorly differentiated cancer (65.8%), followed by moderately differentiated (34.2%). Tumors presented with pT2 (60.5%), followed by pT3 (25.0%) and pT4 (7.9%). Conclusion: Breast cancer among Lao women is characterized by a large percentage of the triple-negative subtype that is less susceptible to hormonal treatments. The empirical treatment with tamoxifen should be reconsidered since it would be less effective to these patients. More importantly, basic pathology services should be the first requirement in Lao PDR in order to provide adequate care.
本研究旨在通过免疫组织化学方法(根据2017年圣加仑指南)评估老挝女性乳腺癌免疫组织化学亚型的患病率,并研究其与临床病理特征的相关性,以帮助指导为患者制定更好的治疗方案。材料与方法:从老挝万象健康科学大学检索2013年至2016年期间76例原发性浸润性乳腺癌的福尔马林固定石蜡包埋组织块。回顾患者信息和既往组织学报告。使用抗雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2/neu)和Ki-67(MIB-1)的抗体进行免疫组织化学检测。结果:患者的平均年龄为49岁,主要组织学类型为浸润性导管癌,非特殊类型(90.7%)。各亚型的比例为激素受体阳性且HER2阴性,44.7%;激素受体阳性且HER2阳性,3.9%;激素受体阴性且HER2阳性,13.2%;三阴性,38.2%。40.8%的病例ER呈阳性,而PR呈阳性的病例为47.4%。超过一半的病例为低分化癌(65.8%),其次是中分化(34.2%)。肿瘤表现为pT2(60.5%),其次是pT3(25.0%)和pT4(7.9%)。结论:老挝女性乳腺癌的特点是三阴性亚型比例较高,对激素治疗不太敏感。应重新考虑他莫昔芬的经验性治疗,因为对这些患者效果较差。更重要的是,老挝应首先提供基础病理服务,以便提供充分的护理。